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Direct Pro-Inflammatory Effects of Prorenin on Microglia
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Abstract
Neuroinflammation has been implicated in hypertension, and microglia have been proposed to play an important role in
the progression of this disease. Here, we have studied whether microglia are activated within cardiovascular regulatory
area(s) of the brain during hypertension, especially in high blood pressure that is associated with chronic activation of the
renin-angiotensin-system. In addition, we determined whether prorenin, an essential component of the renin-angiotensinsystem, exerts direct pro-inflammatory effects on these microglia. Our data indicate that two rodent models which display
neurogenic hypertension and over activation of the renin-angiotensin-system in the brain (sRA mice and spontaneously
hypertensive rats) exhibit microglial activation, and increased levels of pro-inflammatory cytokines, in the paraventricular
nucleus of the hypothalamus, an area crucial for regulation of sympathetic outflow. Further, the renin-angiotensin-system
component prorenin elicits direct activation of hypothalamic microglia in culture and induction of pro-inflammatory
mechanisms in these cells, effects that involve prorenin receptor-induced NFkB activation. In addition, the prorenin-elicited
increases in cytokine expression were fully abolished by microglial inhibitor minocycline, and were potentiated by pretreatment of cells with angiotensin II. Taken together with our previous data which indicate that pro-inflammatory
processes in the paraventricular nucleus are involved in the hypertensive action of renin-angiotensin-system, the novel
discovery that prorenin exerts direct stimulatory effects on microglial activation and pro-inflammatory cytokine production
provides support for the idea that renin-angiotensin-system -induced neurogenic hypertension is not restricted to actions of
angiotensin II alone.
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hypertension, and knockdown of PRR in the brains of these
animals significantly decreased blood pressure and sympathetic
vasomotor tone [11]. A more recent study further confirms the
contribution of PRR in hypertension development showing that
neuron-specific knockdown of PRR lowers Ang II formation and
blood pressure in the deoxycorticosterone acetate-salt mouse
model of hypertension [12–14].
Accumulating evidence suggests that neuroinflammatory processes make a significant contribution to the pathological processes
underlying sustained high blood pressure [11,12]. For example, in
previous studies we demonstrated that viral vector-mediated
increases in the expression of the anti-inflammatory cytokine
interleukin-10 (IL-10) specifically within the PVN significantly
reduced blood pressure in rats made hypertensive by chronic
systemic infusion of angiotensin II (Ang II) [15]. In the same set of
studies we demonstrated that Ang II induced hypertension was
significantly decreased by central (intracerebroventricular; ICV)
infusion of minocycline, a tetracycline antibiotic that inhibits
activation of microglia, the primary resident immune cells in the
brain. Furthermore, this minocycline treatment abolished the
increases in mRNAs for pro-inflammatory cytokines (IL-1b; IL-6;
tumor necrosis factora {TNFa}) and the decrease in IL-10 mRNA

Introduction
Hypertension is a global health problem, and ,20 to 30% of
hypertensive patients are resistant to the available anti-hypertensive medications [1,2]. It is generally accepted that the uncontrolled, resistant hypertension is primarily neurogenic in origin,
involving chronic over activity of the sympathetic nervous system
that initiates and sustains high blood pressure [3–5]. It is well
known that angiotensin II (Ang II) acting via its type 1 receptor
(AT1R) within the paraventricular nucleus of the hypothalamus
(PVN), a brain site that plays a crucial role in regulating
sympathetic outflow [6,7], is a major contributor to this chronic
sympathoexcitation [8]. In addition to this Ang II/AT1R
mechanism it is now evident that another member of the reninangiotensin system (RAS), prorenin, and its receptor PRR [9] play
a role in the central control of neurogenic hypertension. For
example, we have shown that down-regulation of PRR in the
supraoptic nucleus via viral-mediated transduction significantly
attenuates blood pressure development in spontaneous hypertensive rats (SHR) [10]. Furthermore, PRR levels are significantly
higher in the PVN of human renin-angiotensinogen doubletransgenic hypertensive mice, another model of neurogenic
PLOS ONE | www.plosone.org
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Research (IHPREN, Novi, MI); Iba1 antibody was from Wako
(01–1974, Richmond, VA) and Abcam (ab5076, San Francisco,
CA); prorenin receptor antibody from Abcam (ab64957); antiCD11b from Abcam (ab52478); anti-b actin from Sigma (A2228,
St Louis, MO); real-time primers from Applied Biosystems (Grand
Island, NY); and antibodies for flow cytometry and ELISA from
eBioscience (San Diego, CA).

in the PVN elicited by Ang II infusion [15]. It has also been
demonstrated that Ang II-induced hypertension is dependent
upon activation of the inflammatory factor nuclear factor kappa B
(NFkB) in the PVN [16] and direct injection of IL-1b into the
PVN or via the intracerebroventricular route increases mean
arterial pressure [12,15,16]. Our recent studies show that prorenin
also induces the increases in pro-inflammatory cytokine expression
in the nucleus tractus solitarius (NTS), an effect that involves
activation of the nuclear factor kappa B (NFkB) complex [17].
Down-regulation of PRR mediated by viral transfection in the
supraoptic nucleus (SON) significantly slows down high blood
pressure accompanied by decreased inflammatory markers [10].
Collectively these studies support the idea that neuroinflammatory
processes within the PVN are involved in the hypertensive action
of the RAS. It should also be pointed out that the inflammatory
mechanisms associated with neurogenic hypertension are not
restricted to the PVN in the brain, as studies indicate that the
nucleus tractus solitarius, another important cardiovascular
control center, exhibits an inflammatory state in spontaneously
hypertensive rats (SHR), an animal model of this disease [18].
Thus, the idea we are promoting is that a low (but persistent)
level of microglial activation in the PVN occurs via brain RAS
activation in neurogenic hypertension. Questions raised by the
above investigations are whether the inflammation observed in the
PVN during neurogenic hypertension is due to over activation of
the brain (rather than peripheral) RAS, and whether the proinflammatory actions of prorenin include direct effects at
microglia. To address these questions in the present study we
have first assessed the levels of microglial activation and of
cytokine expression in the PVN of both double transgenic mice
(sRA mice) that have selective over activation of the brain RAS
(genetic overexpression of human renin and angiotensinogen
controlled by specific promoters in the brain) [19], and SHR.
Considering recent findings that the PRR in the brain contributes
to the pathogenesis of hypertension [20], we tested whether
prorenin exerts direct pro-inflammatory actions via microglia. We
have utilized cell culture systems, a mouse microglial cell line (N-9)
and microglia isolated from rat hypothalamus, to determine
whether prorenin has direct actions on these cells. The findings
made in this study support the general idea that brain RASmediated activation of pro-inflammatory mechanisms is an
important contributor to neurogenic hypertension.

Microglial cultures
N-9 mouse microglial cells (gift from Dr. Gerry Shaw,
University of Florida) were cultured in Dulbecco’s Modified
Eagles Medium (DMEM) containing 10% fetal bovine serum
(FBS) and an antibiotic cocktail (10,000 IU/ml Penicillin and
10,000 mg/ml Streptomycin; Cellgro, Manassas, VA).
Primary microglial cells were prepared from newborn SD, SHR
and WKY rat pups based on published studies [21]. Meninges and
choroid plexus membranes were removed from brains, and a
hypothalamic block containing the PVN was dissected and minced
with small scissors. The dissected tissues were further dissociated
by filtering through a 100 mm pore nylon mesh (BD, Franklin
Lakes, NJ), followed by centrifuging three times (3006g; 5 min/
spin) at room temperature. After the third centrifugation the
pellets were re-suspended in DMEM containing 10% FBS and an
antibiotic cocktail (1%) as above. The microglial cells were seeded
onto Poly-D-lysine coated 100-mm dishes at a density of 12
56105/ml, and incubated with 95% O2/5% CO2 at 37uC for 7
days without changing the medium. After this time period, floating
microglia in the culture medium were collected and transferred to
6-well plates for 3 hr, and the original dishes were fed with fresh
medium. Microglia were collected in this way at weekly intervals.
Isolated cells were pure microglia based on the co-localization of
Iba1 immunoreactivity with DAPI fluorescence. After attachment
in the new plates, microglia were fed with fresh DMEM/10%
FBS/1% antibiotic cocktail, and incubated for another 2–3 days
before each treatment.

Iba1 immunohistochemistry
PVN: Immunoreactivity for the microglial marker Iba1 in the
PVN of mice (sRA and wild type) or rats (SHR and WKY) was
assessed as follows. Animals were deeply anesthetized with 5%
isoflurane mixed with O2, and perfused transcardially with
heparinized saline followed by 4% paraformaldehyde. Brains
were removed and coronal sections (20 mm) cut through the
hypothalamus to capture the PVN. Sections were incubated with a
polyclonal rabbit anti-Iba1 antibody (1:500, Wako) followed by
incubation with a biotinylated polyclonal rabbit anti-rabbit IgG
(1:200). After additional rinsing, sections were incubated with
avidin-peroxide conjugate containing 0.04% 3,39-diaminobenzidine hydrochloride for 10 min. Sections were mounted on glass
slides with cover slips using Vectashield mounting medium with
DAPI (Vector Labs, Burlingame, CA).
Microglial cell cultures: Cultured N-9 cells or primary microglia
were washed with PBS and then fixed for 10 min with ice cold
0.3% Triton X-100 for 20 min to improve antibody penetration.
Goat serum (5%) in PBS was added to the dish for 30 min at 37uC
to reduce nonspecific binding, followed by an additional wash with
PBS. Immunocytochemistry was performed using either a rabbit
polyclonal antibody against Iba1 (1:2000) or a goat polyclonal
antibody against the PRR (1:500, Abcam). This was followed by
incubation with respective secondary antibodies, Alexa Fluor 488
goat anti-rabbit IgG (1:2000) or Alexa Fluor 594 horse anti-goat
IgG (1:2000) (Molecular Probes, Eugene, OR). PRR and Iba1
immunoreactivities were detected using an Olympus BX41
fluorescence microscope.

Methods
Animals and materials
Male spontaneously hypertensive rats (SHR), Wistar Kyoto
(WKY) rats (8-week-old), and timed pregnant (E13–15) SpragueDawley (SD), SHR and WKY rats were obtained from Charles
River Farms (Wilmington, MA). Double transgenic sRA mice [19]
were bred and housed at the University of Iowa, and were used at
12–21 weeks of age. Male double-transgenic sRA mice were
generated as described previously by cross-mating C57BL/6J mice
that express human renin via the synapsin promoter (sR mice) with
mice expressing human angiotensinogen with its own promoter (A
mice). Littermates with either expression of human angiotensinogen or renin were used as controls. These mice were 12–21 weeks
of age, matched exactly with the sRA mice. All rats and mice were
housed individually in shoebox style forced-air cages, with access
to tap water and food ad libitum and with a 12:12 hr light/dark
cycle. The Institutional Animal Care and Use Committees of the
University of Florida and the University of Iowa approved all
protocols for animal use. The reagents used in this study are as
follows: Human Prorenin was purchased from Innovative
PLOS ONE | www.plosone.org
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TNFa ELISA
Anteroventral 3rd ventricle (AV3V), PVN, NTS and rostral
ventrolateral medulla (RVLM) tissues from control and sRA mice
were dissected and homogenized in RIPA buffer (Thermo,
Rockford, IL). TNFa was measured using an ELISA kit according
to the manufacturer’s instructions (eBioscience) and analyzed by
Fluostar Omega microplate reader (BMG Labtech, Oretenberg,
Germany).

Western Blot for CD11b in cultured microglia
The collected microglial samples were homogenized with
Laemmli Sample buffer (BioRad), loaded onto 4–15% gradient
Criterion gels (Bio-Rad) followed by electrophoretic transfer to
Nitrocellulose membranes (Bio-Rad) using a standard protocol.
Samples were normalized to 1 mg/ml and the loading volume was
20 ml/well. The membranes were incubated with rabbit polyclonal
CD11b (2 mg/ml, Abcam) and mouse anti-b-actin (1:5000, Sigma)
over night at 4uC, followed by reactions with respective goat antirabbit (1:5000) and –mouse (1:5000) (Sigma) peroxidase conjugates. The protein bands for CD11b and b-actin were visualized
by chemiluminescence reagents (Amersham, Piscataway, NJ) and
quantified by Image J software.

Flow Cytometry
To measure cytokine expression, mouse N-9 cells were cultured
with 5 mg/ml brefeldin A (eBioscience), which prevents protein
transportation and leads to cytokine accumulation intracellularly.
Cells were surface-stained with FITC-conjugated anti-CD11b
(BioLegend, San Diego, CA) followed by intracellular staining of
APC-conjugated anti-TNFa (eBioscience) and anti-IL-1b
(eBioscience) with fixation and permeabilization buffer
(eBioscience). The stained samples were analyzed on a Beckman
Coulter CyAn ADP and data were analyzed with FlowJo software.

Calculation of Microglial Fractional Area and Data
Analyses
The activation of PVN microglia, identified by Iba1 immunoreactivity, was analyzed by measuring the fractional area of the
cells using Image J software (NIH). The fractional area of each
image was analyzed based on the ratio of the calculated area of
Iba1-positive staining to the entire image as described previously
[15]. The PVN sections that were analyzed covered the entire
PVN (Rat: Bregma 21.6 to 22.2 mm; Mouse: Bregma 20.82 to
21.06 mm) at 406 magnification. The number of microglia in a
0.260.2 mm2 area was counted from 3 different levels covering
anterior, medial and posterior of PVN in in each animal.
Morphological analysis and quantification of microglia were
performed within the PVN using a fluorescence microscope
(Olympus BX41). Five animals from each group were used for this
analysis, and 15–20 images were taken for each animal.
All N-9 cell and primary microglial culture experiments were
performed in quadruplicate wells and repeated at least three times.
Data are expressed as mean 6 SEM. Statistical significance was
evaluated with the use of Prism software (v5.0, GraphPad).

Figure 1. Levels of pro-inflammatory cytokines within central
cardiovascular control centers of control and sRA mice. Levels
of IL-1b (A) and TNFa (B) mRNAs and TNFa protein (C) were measured
in the AV3V, PVN, NTS and RVLM of control and sRA mice as described
in the Methods. Data are mean 6 SEM., from 6 control and 6 sRA mice
for the mRNA and TNFa protein measurements. * P,0.05 vs. respective
control.
doi:10.1371/journal.pone.0092937.g001

Real-time RT-PCR
For the analysis of mRNA levels, brain tissues or microglial cells
(primary microglia or N-9 cells) were processed as described
previously [15]. In brief, RNA was extracted using RNeasy Mini
Plus kits (Qiagen, Valencia, CA). Purified RNA (200 ng) was
reverse transcribed using a high-capacity iScript cDNA synthesis
kit (Bio-Rad, Hercules, CA). The expression levels of PRR, IL-1b,
IL-10, TNFa, 18 s and GAPDH mRNAs were analyzed via
quantitative real-time RT-PCR using an ABI OneStep Plus
machine (Applied Biosystems). 18 s ribosomal RNA or GAPDH
was used as internal controls.

PLOS ONE | www.plosone.org

Results
Pro-inflammatory cytokine expression in central
cardiovascular regulatory nuclei in hypertensive animals
To characterize neuroinflammation in hypertension, we examined in hypertensive animals the expression of two major proinflammatory cytokines in different brain regions related to
cardiovascular function, the AV3V region, the PVN, the NTS
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Figure 2. Microglial activation in the PVN of sRA mice and SHR. (A) Control vs. sRA mice: Panels (i) and (ii) are representative bright field
micrographs showing Iba1 immunoreactivity in the PVN of control and sRA mice. Panels (iii-v) are bar graphs comparing the microglial fractional area
(iii), and the levels of PRR (iv) and IL-10 (v) mRNAs in the PVN of control and sRA mice. Data are means 6 SEM from the numbers of mice indicated
within the bars. *P,0.05 vs. respective control. (B) SHR vs. WKY rats: Panels (i) and (ii) are representative bright field micrographs showing Iba1
immunoreactivity in the PVN of WKY rats and SHR. Panels (iii-vii) are bar graphs comparing the microglial fractional area (iii), and the levels of PRR (iv),
IL-1b v), TNFa (vi) and IL-10 (vii) mRNAs in the PVN from both strains. Data are means 6 SEM from the numbers of mice indicated within the bars. *P,
0.05 vs. respective control.
doi:10.1371/journal.pone.0092937.g002

and the RVLM. The above brain regions were dissected from
hypertensive sRA and normotensive control mice. We found that
the expression of mRNAs for both IL-1b and TNFa (Figure 1)
were significantly increased in the PVN of hypertensive sRA mice
compared to the normotensive controls, which is consistent with
our previous study [15]. In addition, the mRNA levels of IL-1b in
the NTS and TNFa in the RVLM were significantly greater in the
sRA mice when compared to control mice. In further experiments,
we examined TNFa protein expression in the above four brain
regions of normotensive and sRA mice. The data demonstrated
that TNFa protein levels were significantly greater only in the
PVN of sRA mice compared to the controls. Collectively, these
data suggest that the hypothalamic PVN of hypertensive mice is a
primary site of neuroinflammation amongst the central cardiovascular control centers.

PLOS ONE | www.plosone.org

Animal models of neurogenic hypertension display
increased microglial activation and RAS expression in the
PVN
In this set of studies we determined the profiles of microglial
activation and RAS expression in the PVN of sRA mice and SHR
versus their respective control animals. Both of these animal
models of neurogenic hypertension exhibit enhanced RAS activity
in the CNS, increased sympathetic outflow and resting arterial
blood pressure [16,22]. Iba1 immunostaining revealed that
microglia within the PVN of control mice exist primarily in the
‘‘resting’’ state, as illustrated by small somas and long branched
processes (Figure 2Ai). In contrast, the enlarged soma and shorter
processes of PVN microglia in sRA mice suggest that these cells
are activated (Figure 2Aii). Quantification of microglial activation
was performed using the fractional area method, counting the area
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for PRR (only in sRA mice) at this site (Figure 2Aiv), we
investigated whether there were any direct actions of prorenin
on microglial cell activation. For these experiments we established
in vitro cultures of the mouse-derived microglial N-9 cell line and
also primary microglia dissociated from the hypothalamus of
newborn SD or WKY rats, or SHR. Immunocytochemistry clearly
demonstrated PRR immunoreactivity in the soma of Iba1-positive
N-9 cells and SD rat primary microglia (Figure 3A), with similar
staining obtained in WKY rat and SHR primary microglia (data
not shown). Incubation of either N-9 cells or SD rat primary
microglia with human recombinant prorenin (20 nmol/L) for
24 hr elicited significant increases in the levels of CD11b protein, a
marker expressed by activated microglia [18] (Figure 3B). These
data suggest that prorenin can directly activate microglia.

Prorenin elicits increases in cytokine production in
microglia
Prorenin is well known to increase pro-inflammatory cytokine
production in tissues such as the eye [23], the kidney [24] and the
vasculature [25], effects mediated by PRR. To further evaluate the
direct effects of prorenin on microglial activation, we tested its
effects on pro-inflammatory cytokine levels in cultured microglia.
Incubation of N-9 cells or SD rat primary microglia with human
recombinant prorenin (20 nmol/L; 3 or 24 hr) elicited significant
increases in IL-1b and TNFa mRNA levels, with similar effects at
each time point. Shown in Figure 4A are the data from 24 hr.
These effects of prorenin in N-9 cells and primary microglia were
concentration dependent, with a significant increase obtained at
5 nmol/L. This is illustrated by the data presented in Figure 4B,
which shows the concentration-dependency of prorenin’s effects in
WKY rat and SHR primary microglia. Similar profiles were
obtained in N-9 cells and SD rat microglia (data not shown). It was
also apparent that these effects of prorenin were significantly
greater in SHR than in WKY cells (Figure 4B) and SD rat cells
(data not shown). It is also important to point out that these
stimulatory effects of human prorenin on IL-1b and TNFa mRNA
levels in microglia were not affected by co-treatment with
polymixin B (10 ng/mL), excluding the possibility that they were
due to lipopolysaccharide contamination of the prorenin.
The stimulatory effects of prorenin on IL-1b and TNFa mRNA
levels were unaltered by co-treatment of N-9 or SD rat primary
microglial cells with the AT1R blocker losartan (1 mmol/L)
(Figure 4A). In contrast, as shown in Figure 4C, the stimulatory
effects of prorenin on IL-1b and TNFa mRNA levels in SD rat
microglia were abolished by co-treatment of cells with the putative
PRR blocker HRP (Handle Region Peptide, 20 mmol/L) [26].
Higher concentrations of HRP (50 and 100 mmol/L) also reduced
the effects of prorenin on IL-1b and TNFa mRNA levels, but the
effects were not significant. Collectively, these data suggest that the
observed effects of prorenin are PRR-dependent.
Considering these effects of prorenin on pro-inflammatory
cytokine mRNA levels in cultured microglia, we examined
whether prorenin was able to alter the expression of TNFa
protein. Flow cytometry analyses revealed that treatment of N-9
cells with prorenin (20 nmol/L; 6 hr) elicited a highly significant
increase in TNFa protein (Figure 5A–C). Furthermore, similar
treatment of N-9 cells with prorenin (20 nmol/L) elicited a
significant increase in TNFa protein levels in the growth media,
based on ELISA analyses (Figure 5D).

Figure 3. PRR expression and function in microglia. (A) (i)
Representative fluorescence micrographs showing immunoreactive PRR
(P) and Iba1 co-localized (P+I) in mouse N-9 microglial cells and SD rat
primary microglia. (B) CD11b protein expression was analyzed in N-9
cells and SD rat primary microglia by western blotting following 24 hr
treatment with either control media (DMEM) or prorenin (20 nmol/L).
Top: Representative immunoblots showing CD11b and b-actin (loading
control) protein bands under each treatment condition; Bottom: Bar
graphs are band density ratios of CD11b protein normalized against bactin. Data are means 6 SEM, n = 6 experiments.
doi:10.1371/journal.pone.0092937.g003

occupied by microglia based on Iba1 immunoreactivity. The
microglial fractional area was significantly increased in the PVN of
sRA mice compared to control mice (Figure 2Aiii). In addition,
real-time PCR analyses revealed that sRA mice exhibit increased
levels of PRR mRNA and a decreased level of mRNA for the antiinflammatory cytokine IL-10, in the PVN compared to controls
(Figure 2Aiv-v). The same strategy was used to examine microglial
activation in SHR and WKY rats (Figure 2B). Microglia within
the PVN of SHR, identified by Iba1 immunoreactivity, exhibited
increased activation based on a preponderance of cells exhibiting a
larger soma, compared with a largely ramified appearance and a
smaller soma in WKY rat PVN (Figure 2Bi-iii). Although there
was no obvious difference in PRR mRNA levels in the PVN of
SHR and WKY rats (Figure 2Biv), the levels of IL-1b and
TNFamRNAs were significantly increased, while IL-10 mRNA
was significantly decreased, in the PVN of SHR compared to
WKY rats (Figure 2Biv-vii).

Prorenin activates microglial cells in culture
Since sRA mice and SHR exhibit increased activation of
microglia within the PVN, along with increased levels of mRNAs

PLOS ONE | www.plosone.org
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Figure 4. Prorenin increases pro-inflammatory cytokine levels in microglia. (A) Mouse N-9 cells (i–ii) and SD rat primary microglial cells (iii–
iv) were treated with prorenin (20 nmol/L) in the absence or presence of losartan (1 mmol/L) for 24 hr, followed by analysis of IL-1b and TNFa mRNA
levels as detailed in the Methods. Data are means 6 SEM, n = 3 experiments. * P,0.05 vs. respective control. (B) Levels of IL-1b and TNFa mRNAs
were measured after 6 hr treatment with prorenin (5–50 nmol/L) in cultured microglial cells prepared from WKY rats and SHR. Data are means 6 SEM,
n = 4–5 experiments. All prorenin-treated groups were significantly different vs. their respective controls (P,0.05). * P,0.05 vs. respective WKY rat
group. (C) Levels of IL-1b and TNFa mRNAs were analyzed after 24 hr treatment of SD rat primary microglial cells with control solution (DMEM) or
prorenin (20 nmol/L) in the absence or presence of the indicated concentrations of HRP. Data are means 6 SEM from n = 3 experiments. * P,0.05 vs.
respective control; { P,0.05 vs. prorenin-alone group.
doi:10.1371/journal.pone.0092937.g004

cells. The results demonstrated that prorenin induced a dosedependent increase in both subunits (Figure 6A). Moreover,
prorenin (20 nmol/L) promoted nuclear translocation of NFkB
immunoreactivity (Figure 6B), suggesting that activation of NFkB
is involved in prorenin-induced transcription. In order to

Prorenin elicited NFkb activation in microglia
To determine if prorenin/PRR-elicited pro-inflammatory
cytokine production is NFkB-dependent, we examined the
expression of mRNAs for the subunits of the NFkB complex,
NFkB1 and NFkBia mRNA, in both N-9 and primary microglial
PLOS ONE | www.plosone.org
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abolished the prorenin (20 nmol/L) induced increases in these
cytokine mRNAs (Figure 8).

Discussion
The major findings of the present study are: (i) that two rodent
models which display neurogenic hypertension and over activation
of the RAS in the brain (sRA mice and SHR) exhibit microglial
activation, and increased levels of pro-inflammatory cytokines in
the PVN; (ii) that the RAS component prorenin elicits direct
activation of microglia and induction of pro-inflammatory
mechanisms, effects that involve PRR-induced NFkB activation;
(iii) that prorenin causes greater responses in cytokine production
in Ang II-pretreated microglia; and (iv) prorenin-elicited increases
in cytokine expression were fully abolished by microglial inhibitor
minocycline. Taken together with our previous data which
indicate that pro-inflammatory processes in the PVN are involved
in the hypertensive action of RAS [12], the novel discovery that
prorenin exerts direct stimulatory effects on microglial activation
and pro-inflammatory cytokine production provides support for
the idea that RAS-induced neurogenic hypertension is not
restricted to actions of Ang II alone.
The present work raises many questions that will require further
studies to answer. First of all, our in vitro studies suggest that the
direct pro-inflammatory effects of prorenin in microglia are
mediated through PRR, since they were not affected by the
AT1R antagonist losartan and were attenuated/blocked by the
putative PRR blocker HRP [27]. When considering the debatable
specificity of HRP in blocking PRR, an alternative approach to
address whether prorenin induced pro-inflammatory effects are
mediated by PRR would be to down-regulate PRR in the
microglia and then examine the effects on inflammation formation. While our in vitro data suggest a direct induction of proinflammatory cytokines by prorenin, it is likely that in the in vivo
situation prorenin also operates indirectly via the generation of
Ang II.
Our studies also indicated that while the pro-inflammatory
actions of prorenin in microglia were AT1R-independent, they
were potentiated by pretreatment of the cultures with Ang II
(Figure 7). This ‘‘priming’’ action of Ang II appears similar to that
of interferon gamma (IFNc), a physiological activator of macrophages. By itself, IFNc has limited effects on cytokine production.
However, it primes the cells to produce a much stronger effects to
a second stimulation, such as elicited by LPS, Cytosine-phosphateguanosine (CpG) and TNFa [28–30]. A possible explanation is
that pretreatment of microglia with Ang II modulates an
intracellular event that potentiates the pro-inflammatory effects
of prorenin. Our data (Figure 6) indicate that the pro-inflammatory action of prorenin action is involves an NFkB-dependent
mechanism. Thus, it will be interesting to determine whether the
priming actions of Ang II also involve an NFkB-dependent
mechanism, or a mechanism that is independent of that activated
by prorenin.
An important question raised by these studies is whether the
pro-inflammatory cytokines that are induced by RAS activation
exert stimulatory effects on sympathetic outflow. We can speculate
that pro-inflammatory cytokines, or other microglial-derived
factors such as chemokines, elicit sustained increases in the activity
of PVN pre-sympathetic neurons that enhance the direct neuronal
actions of Ang II via AT1R to produce chronic sympathoexcitation. However, while studies have demonstrated cardiovascular
actions of cytokines injected into the PVN [12,31], and it has been
demonstrated that IL-1b depolarizes parvocellular neurons at this
site [32], the presence of pro-inflammatory cytokine receptors on

Figure 5. Prorenin increases TNFa levels in N-9 microglial cells.
N-9 cells were treated with control medium or prorenin (20 nmol/L) for
6 hr, followed by analysis of TNFa-positive cells using flow cytometry
(A–C) and released TNFa by ELISA assay (D). FSC: forward scatter. Data
are means 6 SEM from n = 3 experiments. * P,0.05 vs. control.
doi:10.1371/journal.pone.0092937.g005

substantiate the role of NFkB in this process, we treated both N-9
and primary microglia with prorenin (20 nmol/L) in the presence
or absence of the NFkB inhibitor PDTC (50 mmol/L). The data
shown in Figure 6C indicates that PDTC fully abolished the
increases in cytokine mRNAs in both cell types, suggesting that the
cytokine upregulation by prorenin/PRR is dependent on NFkB
complex activation.

Ang II potentiates prorenin-induced cytokine production
in microglia
Considering that Ang II is a primary effector of the RAS, we
tested whether Ang II and prorenin exert any synergistic actions.
Flow cytometry analyses revealed that simultaneous co-treatment
of N-9 cells with Ang II (100 nmol/L) and prorenin (20 nmol/L)
for 6 hr produced no greater increase in TNFa protein levels
when compared with prorenin alone (data not shown). Interestingly, after pre-treatment of N-9 cells with Ang II (100 nmol/L,
12 hr) the stimulatory effect of prorenin on TNFa levels was
significantly enhanced versus that obtained in cells that had been
pre-treated for 12 hr with control solution (Figure 7).

Minocycline abolishes prorenin-induced increases in
cytokine production
In order to investigate whether the prorenin-induced increases
in pro-inflammatory cytokine levels depends on microglial
activation, we examined the mRNA expression of IL-1b and
TNFa elicited by prorenin in the presence of minocycline, a potent
inhibitor of microglial activation. Co-treatment of N-9 cells or
primary microglia with minocycline (1 mmol/L) completely

PLOS ONE | www.plosone.org

7

October 2014 | Volume 9 | Issue 10 | e92937

PVN Microglia and Hypetension

Figure 6. NFkB activation mediated prorenin-induced cytokine production. (A) N-9 (i–ii) and primary microglial cells (iii–iv) were treated
with prorenin (10–50 nmol/L), and cell lysates were analyzed by real-time RT-PCR for NFkB1 and NFkBia. Data are mean 6 SEM, * P,0.05 vs. control,
n = 5 each group. (B) Representative images of NFkB immunoreactivity and Dapi nuclear stain in N-9 (i) and primary microglial cell (ii) 24 hr post
control (upper panels) and prorenin (20 nmol/L, lower panels) treatments. (C) N-9 (i–ii) and primary microglia (iii–iv) were treated with control
solution (DMEM) or prorenin (20 nmol/L) in the presence or absence of PDTC (50 mmol/L), and IL-1b and TNFa mRNA levels were quantified by realtime RT-PCR. Experiments were performed triplicate. Data are mean 6 SEM, * P,0.05 vs. control, n = 5 each group.
doi:10.1371/journal.pone.0092937.g006

induced pro-inflammatory actions in the PVN and activation of
pre-sympathetic neurons at that site.
The current studies were focused on microglia, the major
resident immune cells in the brain, because of our previous
observation that inhibition of microglial activation by minocycline
treatment blunted Ang II-induced hypertension. However, it is
likely that other immune cells may also contribute to RAS-induced
neuroinflammation. For example, it is well known that astrocytes
are also a major contributor to resident immune mechanisms in
the central nervous system [34], and contain both AT1R and PRR

pre-autonomic efferent neurons in the PVN has not been
demonstrated. In fact, one study has demonstrated the presence
of IL-1b receptors on magnocellular secretory neurons at this site
[33]. Thus, it is possible that pro-inflammatory cytokines, induced
by RAS activation, have no direct stimulatory effects on presympathetic neurons but operate to enhance sympathoexcitation
via effects on interneurons or by inhibition of GABAergic input, as
is the case in the aforementioned depolarization of PVN neurons
by IL-1b [32]. A major goal of our current and future research will
be to examine whether there is a direct linkage between proreninPLOS ONE | www.plosone.org
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Figure 7. Ang II potentiates prorenin-induced TNFa production
in microglia. Mouse N-9 cells were pretreated with control media
(DMEM) or Ang II (100 nmol/L) for 12 h, followed by treatment with
DMEM or prorenin (20 nmol/L) for 6 hr. Next, TNFa positive cells were
analyzed by flow cytometry. Data are means 6 SEM from n = 6
experiments. * P,0.05 vs. control; { P,0.05 vs. prorenin without Ang II
pretreatment.
doi:10.1371/journal.pone.0092937.g007

[20,35]. In addition, perivascular macrophages have been shown
to be another source of inflammatory mediators in the CNS, and
factors released from these cells such as cyclooxygenase 2 and
prostaglandin E2 can infiltrate the blood-brain barrier and
increase neuronal activity in the PVN [36]. Since microglia are
resident immune cells and it is very likely that they are one of the
earliest players, and might recruit patrolling perivascular macrophages to exaggerate the inflammatory reactions with the progress
of hypertension. Therefore, the present study does not exclude the
possibility that perivascular macrophages contribute to the RASdependent inflammation. A further possibility is that prorenin
induced activation of microglia functions as an initiating event,
recruiting and activating the adaptive immune system such as
circulating T lymphocytes [37] or monocytes [38] to the PVN to
exacerbate the immune reaction. Clearly, further studies/experiments need to be performed to determine the contribution from
individual immune cell populations.
In conclusion, the data presented here provide evidence for
direct actions of prorenin at microglia to exert pro-inflammatory
actions. When considering that animal models of neurogenic
hypertension display increased RAS activation in the PVN and
also increased activation of microglia and levels of pro-inflammatory mediators at this site, our findings support the notion that the
hypertensive action of prorenin via the brain includes a
neuroimmune component at the PVN.

Figures 8. Minocycline inhibits prorenin induced pro-inflammatory cytokine production in microglial cells. Mouse N-9 (A)
and SD rat primary microglial cells (B) were treated with control
solution (DMEM) or prorenin (20 nmol/L) in the presence or absence of
minocycline (1 mmol/L) for 24 hr; cell lysates were analyzed for IL-1b
and TNFa mRNAs. Data are means 6 SEM from 6 experiments. * P,0.05
vs. control.
doi:10.1371/journal.pone.0092937.g008
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